ADAMTS4

Across TCGA pan-cancer cohorts, ADAMTS4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADAMTS4 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADAMTS4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADAMTS4 expression acts as an unfavorable survival marker.

LUAD, PDAC, and LSCC are the cancer types where ADAMTS4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.407	0.857	.001	29	view →
PDAC	DFS	Tertile	All	0.695	0.841	.003	26	view →
LSCC	DFS	Quartile	III,IV	0.774	1.000	.043	2	view →
HNSC	DFS	Median	II,III,IV	0.576	0.745	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADAMTS4–LUAD (OS)

Open the LUAD breakdown →